neomycin sulfate, polymyxin b sulfate and dexamethasone
neomycin sulfate, polymyxin b sulfate and dexamethasone is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand names including Maxitrol, Neomycin and Polymyxin B Sulfates and Dexamethasone, MAXITROL. Available dosage forms: suspension, ointment.
Drug Details
- Generic Name
- neomycin sulfate, polymyxin b sulfate and dexamethasone
- Brand Names
- Maxitrol, Neomycin and Polymyxin B Sulfates and Dexamethasone, MAXITROL, neomycin sulfate, polymyxin b sulfate and dexamethasone
- Application Number
- NDA050023
- Sponsor
- Harrow Eye, LLC
- NDC Codes
- 7
- Dosage Forms
- SUSPENSION, OINTMENT
- Routes
- OPHTHALMIC
- Active Ingredients
- NEOMYCIN SULFATE, POLYMYXIN B SULFATE, DEXAMETHASONE
Indications and Usage
INDICATIONS AND USAGE: For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus,Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa . This product does not provide adequate coverage against Serratia marcescens , and Streptococci, including Streptococcus pneumoniae .
Warnings
WARNINGS: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections. Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. Acute purulent infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended. Neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye. Products containing neomycin sulfate may cause cutaneous sensitization.